Qingdao Baheal Medical INC. (SHE:301015)
China · Delayed Price · Currency is CNY 23.98
+0.05 (0.21%)
At close: Feb 6, 2026
SHE:301015 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7,552 | 8,068 | 8,226 | 7,494 | 7,030 | 5,864 |
Other Revenue | 26.03 | 26.03 | 29.96 | 15.19 | 22 | 15.19 |
| 7,578 | 8,094 | 8,256 | 7,510 | 7,052 | 5,879 | |
Revenue Growth (YoY) | -9.95% | -1.96% | 9.94% | 6.50% | 19.94% | 21.26% |
Cost of Revenue | 4,802 | 5,228 | 5,505 | 5,426 | 5,277 | 4,415 |
Gross Profit | 2,775 | 2,866 | 2,751 | 2,084 | 1,774 | 1,464 |
Selling, General & Admin | 1,900 | 1,797 | 1,595 | 1,319 | 1,130 | 1,013 |
Research & Development | 42.69 | 36.14 | 42.45 | 3.32 | - | - |
Other Operating Expenses | 32.48 | 39.3 | 27.94 | 36.05 | 31.54 | 27.11 |
Operating Expenses | 1,980 | 1,884 | 1,698 | 1,371 | 1,160 | 1,050 |
Operating Income | 795.15 | 981.91 | 1,053 | 712.6 | 614.75 | 413.73 |
Interest Expense | -97.24 | -80.09 | -71.73 | -58.07 | -61.08 | -62.24 |
Interest & Investment Income | 32.17 | 72.84 | 57.03 | 9.44 | 10.92 | 17.98 |
Currency Exchange Gain (Loss) | -2.88 | -2.88 | -2.9 | 6.42 | -2.38 | -3.23 |
Other Non Operating Income (Expenses) | -0.24 | -2.32 | -8.9 | -4.99 | -15.22 | -5.88 |
EBT Excluding Unusual Items | 726.95 | 969.46 | 1,026 | 665.4 | 547 | 360.35 |
Gain (Loss) on Sale of Investments | 67.5 | -6.59 | 0.62 | -10.75 | 5.87 | 4.21 |
Gain (Loss) on Sale of Assets | 0.32 | 0.93 | -6.57 | 0.57 | 0.1 | 0.48 |
Asset Writedown | -32.87 | -0.46 | -0.35 | -0.04 | -0.01 | -0.14 |
Other Unusual Items | -7.9 | 3.29 | 8.26 | 13.38 | 12.46 | 5.98 |
Pretax Income | 754 | 966.63 | 1,028 | 668.55 | 565.42 | 370.89 |
Income Tax Expense | 116.93 | 199.6 | 257.26 | 183.15 | 150.4 | 93.66 |
Earnings From Continuing Operations | 637.07 | 767.03 | 770.73 | 485.4 | 415.02 | 277.22 |
Minority Interest in Earnings | -110.04 | -75.44 | -58.67 | 16.68 | 6.63 | -4.51 |
Net Income | 527.03 | 691.59 | 712.06 | 502.09 | 421.64 | 272.71 |
Net Income to Common | 527.03 | 691.59 | 712.06 | 502.09 | 421.64 | 272.71 |
Net Income Growth | -34.71% | -2.87% | 41.82% | 19.08% | 54.61% | 29.94% |
Shares Outstanding (Basic) | 523 | 524 | 524 | 523 | 496 | 470 |
Shares Outstanding (Diluted) | 544 | 540 | 535 | 523 | 496 | 470 |
Shares Change (YoY) | -0.31% | 0.92% | 2.37% | 5.44% | 5.50% | -0.49% |
EPS (Basic) | 1.01 | 1.32 | 1.36 | 0.96 | 0.85 | 0.58 |
EPS (Diluted) | 0.97 | 1.28 | 1.33 | 0.96 | 0.85 | 0.58 |
EPS Growth | -34.50% | -3.76% | 38.54% | 12.94% | 46.55% | 30.58% |
Free Cash Flow | 568.3 | 509.86 | 614.01 | 200.43 | 153.81 | -133.19 |
Free Cash Flow Per Share | 1.04 | 0.94 | 1.15 | 0.38 | 0.31 | -0.28 |
Dividend Per Share | 0.762 | 0.762 | - | 0.762 | 0.667 | - |
Dividend Growth | - | - | - | 14.24% | - | - |
Gross Margin | 36.62% | 35.41% | 33.32% | 27.75% | 25.16% | 24.90% |
Operating Margin | 10.49% | 12.13% | 12.75% | 9.49% | 8.72% | 7.04% |
Profit Margin | 6.96% | 8.54% | 8.63% | 6.69% | 5.98% | 4.64% |
Free Cash Flow Margin | 7.50% | 6.30% | 7.44% | 2.67% | 2.18% | -2.27% |
EBITDA | 841.78 | 1,033 | 1,110 | 735.93 | 636.6 | 433.31 |
EBITDA Margin | 11.11% | 12.77% | 13.45% | 9.80% | 9.03% | 7.37% |
D&A For EBITDA | 46.64 | 51.36 | 57.65 | 23.33 | 21.85 | 19.59 |
EBIT | 795.15 | 981.91 | 1,053 | 712.6 | 614.75 | 413.73 |
EBIT Margin | 10.49% | 12.13% | 12.75% | 9.49% | 8.72% | 7.04% |
Effective Tax Rate | 15.51% | 20.65% | 25.03% | 27.39% | 26.60% | 25.25% |
Revenue as Reported | 7,578 | 8,094 | 8,256 | 7,510 | 7,052 | 5,879 |
Advertising Expenses | - | 0.26 | - | 1.01 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.